313 related articles for article (PubMed ID: 17368349)
1. 17D yellow fever vaccines: new insights. A report of a workshop held during the World Congress on medicine and health in the tropics, Marseille, France, Monday 12 September 2005.
Barrett AD; Monath TP; Barban V; Niedrig M; Teuwen DE
Vaccine; 2007 Apr; 25(15):2758-65. PubMed ID: 17368349
[TBL] [Abstract][Full Text] [Related]
2. Prevention of yellow fever in persons traveling to the tropics.
Monath TP; Cetron MS
Clin Infect Dis; 2002 May; 34(10):1369-78. PubMed ID: 11981733
[TBL] [Abstract][Full Text] [Related]
3. Review of the risks and benefits of yellow fever vaccination including some new analyses.
Monath TP
Expert Rev Vaccines; 2012 Apr; 11(4):427-48. PubMed ID: 22551029
[TBL] [Abstract][Full Text] [Related]
4. Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP).
Staples JE; Gershman M; Fischer M;
MMWR Recomm Rep; 2010 Jul; 59(RR-7):1-27. PubMed ID: 20671663
[TBL] [Abstract][Full Text] [Related]
5. Next generation live-attenuated yellow fever vaccine candidate: Safety and immuno-efficacy in small animal models.
Piras-Douce F; Raynal F; Raquin A; Girerd-Chambaz Y; Gautheron S; Sanchez MEN; Vangelisti M; Mantel N
Vaccine; 2021 Mar; 39(13):1846-1856. PubMed ID: 33685778
[TBL] [Abstract][Full Text] [Related]
6. Development of a Bicistronic Yellow Fever Live Attenuated Vaccine with Reduced Neurovirulence and Viscerotropism.
Wang HJ; Guo Y; He MJ; Liu ZY; Ye Q; Huang XY; Deng YQ; Li XF; Qin CF
Microbiol Spectr; 2022 Oct; 10(5):e0224622. PubMed ID: 35980184
[TBL] [Abstract][Full Text] [Related]
7. Randomized, double-blind, phase III, pivotal field trial of the comparative immunogenicity, safety, and tolerability of two yellow fever 17D vaccines (Arilvax and YF-VAX) in healthy infants and children in Peru.
Belmusto-Worn VE; Sanchez JL; McCarthy K; Nichols R; Bautista CT; Magill AJ; Pastor-Cauna G; Echevarria C; Laguna-Torres VA; Samame BK; Baldeon ME; Burans JP; Olson JG; Bedford P; Kitchener S; Monath TP
Am J Trop Med Hyg; 2005 Feb; 72(2):189-97. PubMed ID: 15741556
[TBL] [Abstract][Full Text] [Related]
8. Is the absence or intermittent YF vaccination the major contributor to its persistent outbreaks in eastern Africa?
Baba MM; Ikusemoran M
Biochem Biophys Res Commun; 2017 Oct; 492(4):548-557. PubMed ID: 28109882
[TBL] [Abstract][Full Text] [Related]
9. Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, double-blind clinical trial.
Monath TP; Nichols R; Archambault WT; Moore L; Marchesani R; Tian J; Shope RE; Thomas N; Schrader R; Furby D; Bedford P
Am J Trop Med Hyg; 2002 May; 66(5):533-41. PubMed ID: 12201587
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity and safety of concomitant and sequential administration of yellow fever YF-17D vaccine and tetravalent dengue vaccine candidate TAK-003: A phase 3 randomized, controlled study.
Tricou V; Essink B; Ervin JE; Turner M; Escudero I; Rauscher M; Brose M; Lefevre I; Borkowski A; Wallace D
PLoS Negl Trop Dis; 2023 Mar; 17(3):e0011124. PubMed ID: 36888687
[TBL] [Abstract][Full Text] [Related]
11. Vaccination with Replication Deficient Adenovectors Encoding YF-17D Antigens Induces Long-Lasting Protection from Severe Yellow Fever Virus Infection in Mice.
Bassi MR; Larsen MA; Kongsgaard M; Rasmussen M; Buus S; Stryhn A; Thomsen AR; Christensen JP
PLoS Negl Trop Dis; 2016 Feb; 10(2):e0004464. PubMed ID: 26886513
[TBL] [Abstract][Full Text] [Related]
12. Yellow fever vaccine: past, present and future.
Roukens AH; Visser LG
Expert Opin Biol Ther; 2008 Nov; 8(11):1787-95. PubMed ID: 18847312
[TBL] [Abstract][Full Text] [Related]
13. Molecular characterization of the 17D-204 yellow fever vaccine.
Salmona M; Gazaignes S; Mercier-Delarue S; Garnier F; Korimbocus J; Colin de Verdière N; LeGoff J; Roques P; Simon F
Vaccine; 2015 Oct; 33(41):5432-5436. PubMed ID: 26314624
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity and Protection After Vaccination With a Modified Vaccinia Virus Ankara-Vectored Yellow Fever Vaccine in the Hamster Model.
Julander JG; Testori M; Cheminay C; Volkmann A
Front Immunol; 2018; 9():1756. PubMed ID: 30116244
[TBL] [Abstract][Full Text] [Related]
15. Sanger-based sequencing technology for yellow fever vaccine genetic quality control.
Pestana CP; Lawson-Ferreira R; Lessa-Aquino C; Leal MDLF; Freire MDS; Homma A; Medeiros MA
J Virol Methods; 2018 Oct; 260():82-87. PubMed ID: 30009851
[TBL] [Abstract][Full Text] [Related]
16. Yellow fever vaccine: an effective vaccine for travelers.
Verma R; Khanna P; Chawla S
Hum Vaccin Immunother; 2014; 10(1):126-8. PubMed ID: 24056028
[TBL] [Abstract][Full Text] [Related]
17. Randomized, double-blind, multicenter study of the immunogenicity and reactogenicity of 17DD and WHO 17D-213/77 yellow fever vaccines in children: implications for the Brazilian National Immunization Program.
Collaborative Group for Studies with Yellow Fever Vaccine
Vaccine; 2007 Apr; 25(16):3118-23. PubMed ID: 17316925
[TBL] [Abstract][Full Text] [Related]
18. Attenuation of Live-Attenuated Yellow Fever 17D Vaccine Virus Is Localized to a High-Fidelity Replication Complex.
Davis EH; Beck AS; Strother AE; Thompson JK; Widen SG; Higgs S; Wood TG; Barrett ADT
mBio; 2019 Oct; 10(5):. PubMed ID: 31641088
[TBL] [Abstract][Full Text] [Related]
19. Yellow fever vaccines and international travelers.
Barnett ED; Wilder-Smith A; Wilson ME
Expert Rev Vaccines; 2008 Jul; 7(5):579-87. PubMed ID: 18564013
[TBL] [Abstract][Full Text] [Related]
20. Yellow fever: the recurring plague.
Tomori O
Crit Rev Clin Lab Sci; 2004; 41(4):391-427. PubMed ID: 15487593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]